Your SlideShare is downloading. ×
Cell Based Assays Americas (2012)
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Cell Based Assays Americas (2012)

267
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
267
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. CALL NOW FOR EARLY BIRD Cell Based DISCOUNTS Assays Americas Market prospects for more cost-effective drug discovery, development and toxicity testing using advances in methodology July 19th - 20th, 2012, The Seaport Hotel, Boston, USA BOOK NOW! Key Speakers Sashi Nadanaciva, Principal Scientist, Pfizer R&D Douglas Auld, Sr. Research Investigator I, Novartis Arijit Chakravarty, Senior Scientist, Millennium Pharmaceuticals Regis Doyonnas, Senior Principle Scientist, Pfizer Okechukwu Ukairo, Sr. Principal Scientist, Hepregen Corporation Robert Graves, Senior Scientist, GE Healthcare Marcie Glicksman, Director Lab for Drug Discovery, Harvard NeuroDiscovery Center Deborah Moshinsky, Founder and President, Cell Assay Innovations Jim Beltzer, Senior Cell Processing Specialist, Terumo BCT Robert Graves, Senior Scientist, GE Healthcare Tetsuro Wakatsuki, Co-Founder & Chief Scientific Officer, InvivoSciences Grace Wong, CEO, ActoKine Therapeutics Mehmet Fatih Yanik, Assoc. Professor, MIT Shantanu Singh, Research Fellow, Imaging Platform, Broad Institute of Harvard and MIT Grant Cameron, RAFT Development Director, TAP Biosystems Thorsten Gorba, Director, CNS Assay Screening and Development, StemCells, Inc. Peter Sartipy, Senior Principal Scientist, Department Head, Cellectis Stem CellsSilver Sponsor Exhibitors matrical bioscience Driving the Industry Forward | www.futurepharmaus.com Media Partners Organised ByTo Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/CellBasedAssaysUSA
  • 2. Conference Introduction Cell Based Assays Americas July 19th - 20th, 2012, Boston, USA Dear Colleague,  Drugs recalls due to toxicity not only have a huge effect on the cost of Who should attend this conference? developing new therapeutics but it also leads to many years of wasted research. That is why it is vital to get things right from the outset with more Presidents, Chief Executives, Chief Scientific Officers, Chief precise testing of new leads using more accurate in-vitro models. High Throughput Screening using biochemical assays has been a mainstay of the Operating Officers, Senior Vice Presidents, Vice Presidents, pharmaceutical industry in the past, but with the cost of developing a single Heads, Senior Directors, Directors, Clinicians, Principal lead reaching exorbitant amounts, it is now necessary to look at more cost- efficient methods that more accurately represent the in-vivo environment. Scientists, Principal Investigators, Managers, Project/Team  cell based assay platform has now been integrated into the HTS The Leaders in: pipeline to provide more accurate analyses of new drug leads and their activity in-vivo. It already makes up 50% of the HTS activity by the top • Bioanalytical Development pharmaceutical companies and the industry is set to grow at a rate of 15% CAGR by 20151. In addition to being a more accurate platform for • High-Throughput/High-Content Screening Operations developing drugs, it also reduces costs incurred by toxicology testing in animals and mitigates the risk of future recalls. • Compound Profiling Why you should attend this conference: • Drug Discovery/Validation • Future growth opportunities in the cell based assays market •  ow to reduce costs in the drug development process and produce more H • Drug Delivery accurate results earlier. • Explore new techniques for lead discovery and target identification • Lead Generation •  iscover advances in core components required for the cell based assay D • In Vitro Sciences platform •  ovel outputs using label-free detection methods that reduce interference N • ADMET in cellular signaling •  evelopments in software analysis for the outputs generated by different D • Pre-clinical Development cell based assays • Medicinal Chemistry •  ell culture advances and methodology as the platform moves from 2D C to 3D • Toxicology •  ell procurement using induced pluripotent stem cells to mimic human C disease pathology • Stem Cell Technologies & Platforms •  ecreating more accurate models of human disease and their response R to new drugs • Pharmacovigilance and Safety Testing • Advances in process automation and management of data • Chemistry and Bioapplications I look forward to meeting you at the conference Best regards • GPCR/Kinases/Molecular Pharmacology • External/Contract Research • Pharmacokinetics/Pharmacodynamics Shahidul Islam • Global Research and Development Conference Producer • Business Development • Investment and Venture Capital
  • 3. Day 1 Cell Based Assays Americas Thursday July 19th, 2012 09:00 Registration and refreshments Gene-induction-assay: A useful approach for screening 14:00  existing drugs for new therapeutic indications in the09:30 Opening address from the Chair areas of radioprotection & anti-viral activity Grace Wong • dentify AK-1 inducible genes involved in radioprotection and AK-2 I CEO inducible genes involved in anti-viral activity ActoKine Therapeutics •  alidate biological properties by gene silencing. Gene-induction-assay V approach will be used to screen existing drugs for properties that mimic09:40 Session to be announced the actions of AK-1 and AK-2 proteins. Arijit Chakravarty Senior Scientist •  iscover new therapeutic indications for known drugs in the areas of D Millennium Pharmaceuticals radioprotection and prevention of infections by existing or emerging viruses •  xamine combined therapy of AK-1 or AK-2 with known drugs used in E10:20  High Content Screening Strategy for the rare A the immunotherapy of cancer and viral diseases Neurological disease Amyotrophic Lateral Sclerosis Grace Wong •  aboratory for Drug Discovery for Neurodegeneration (LDDN) is an L CEO academic drug discovery center that collaborates with the academic ActoKine Therapeutics community to accelerate the identification of novel therapeutics. •  myotrophic Lateral Sclerosis (ALS, Lou Gehrig’s disease) is a rare A neurodegenerative disease. There are at least six genes that can cause 14:40 Approaches to interpreting cell-based assay results ALS. The genetic causes of ALS can provide a number of clues to the mechanism of the disease as well as good potential therapeutic targets. in chemical biology •  e have done a high throughput high content screening assay to screen W • nvestigation of new reporter enzymes to improve reporter-gene assay I our compound library for modulators of one of the genes targets that is a design and result interpretation DNA/RNA binding protein, TDP-43 (TAR DNA-binding protein 43). •  se of focus libraries in the characterization of cell-based assays U •  he stages to develop a high throughput high content assay will be T discussed along with the results from the screen. •  igh-content approaches H Marcie Glicksman Douglas Auld Director Lab for Drug Discovery Sr. Research Investigator I Harvard NeuroDiscovery Center Novartis11:00 Morning refreshments 15:00 Afternoon Refreshments11:20 High Content Imaging Assays that identify Compounds which impair Mitochondrial and 15:20 Microfluidic system for on-chip high-throughput Lysosomal function whole-animal sorting and screening at sub-cellular Sashi Nadanaciva Principal Scientist resolution Pfizer R&D •  creening whole organisms for HCA S •  pplication to drug discovery and toxicity testing A12:00 Developing Reproducible and Scalable Methods to Mehmet Fatih Yanik Culture Stem Cells: From the Microwell Plate to the Assoc. Professor Bioreactor MIT •  pproaches to finding the right culture conditions to meet your needs A •  atrix, media and cell line considerations for optimal growth and M performance 16:00 Cellular systems that address the efficacy, selectivity, •  rivers for scale up, manufacturing concerns and potential bottlenecks D and mechanism of action of kinase inhibitors •  ags, bioreactors, micro-carriers, hollow fiber and fixed bed bioreactors B • Development and validation of a kinase cell-based assay platform Jim Beltzer Senior Cell Processing Specialist •  tility for drug discovery (HTS, MOA determination, and lead optimization) U Terumo BCT • Utility of the platform for selectivity analysis in cells • Multiplex screening to improve efficiencies12:40 Drug Discovery through 3D Engineered Tissue-Based • Application to HTS for drug resistant mutant multiplexed analysis Compound Analysis •  irst-in-class drug discovery through engineered tissue-based high F Deborah Moshinsky content analysis Founder and President •  ardiotoxicity assessments with human engineered heart tissues C Cell Assay Innovations •  ulti-stage phenotypic screening for discovering a cardiac fibrosis M treatment •  ast Track drug discovery in a skeletal muscle disease treatment F 16:40 Closing remarks from the Chair Tetsuro Wakatsuki Co-Founder & Chief Scientific Officer InvivoSciences 16:50 Networking Drinks Take your discussions further and build new13:00 Networking lunch relationships in a relaxed and informal setting Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2012
  • 4. Day 2 Cell Based Assays Americas Friday July 20th, 2012 09:00 Registration and refreshments 14:20 High-content screening in physiologically relevant contexts 09:30 Opening address from the chair •  o-cultures of stem cells can be screened by microscopy to study C Sashi Nadanaciva hematopoiesis and leukemia Principal Scientist •  o-cultures of hepatocytes can be screened by microscopy to study liver C Pfizer R&D functions and hepatotoxicity •  . elegans can be screened by microscopy to study infection and C 09:40 Development of phenotypic screening platforms for metabolism in intact animals the evaluation of putative autophagy enhancers Regis Doyonnas Shantanu Singh Senior Principle Scientist Research Fellow, Imaging Platform Pfizer Broad Institute of Harvard and MIT 10:20  Novel Micropatterened Hepatocyte Co-culture A System for Drug Metabolism and Toxicity Studies 15:00 Afternoon refreshments •  eed for clinically-relevant and higher throughput liver models for drug N screening •  verview of a microscale hepatocyte co-culture system O 15:20 Stem cell derived cardiomyocytes in cell based assays •  dvantages of the co-culture system: Relevant examples of how the A mimicking in vivo tissue-like responses microscale hepatocyte co-culture system could aid in toxicity prediction and prediction of human in vivo metabolites •  erivation and characteristics of cardiomyocytes from human pluripotent D stem cells Okechukwu Ukairo Sr. Principal Scientist •  pportunities and limitation of current state-of-the-art stem cell derived O Hepregen Corporation cardiomyocytes in cell based assays •  ase studies of stem cell derived cardiomyocytes as alternatives to in vivo C 11:00 Morning refreshments and ex vivo animal models Peter Sartipy 11:20  novel, rapid and automated method for creating A Senior Principal Scientist, Department Head 3D tissue models to study complex cell behaviour Cellectis Stem Cells • What type of information can 3D tissue models provide? • What is preventing widespread adoption of 3D tissue models? • The route to scalable and tuneable 3D tissue models 16:00 Panel Discussion: Opportunities and challenges for Grant Cameron human stem cells in drug screening RAFT Development Director TAP Biosystems •  o models based on human dervied stem cells accurately reflect in-vivo D conditions? 12:00 Session to be announced •  hat hurdles remain in the path to replacing animal testing with cellular W Robert Graves assays? Senior Scientist •  thical dilemmas related to embryonic stem cells E GE Healthcare Peter Sartipy, Senior Principal Scientist, Department Head 12:40 Networking lunch Cellectis Stem Cells Marcie Glicksman, Director Lab for Drug Discovery 13:40 CNS based assays for automated drug discovery and Harvard NeuroDiscovery Center profiling Thorsten Gorba, Director, CNS Assay Screening and Development, •  tem cell-based integrated platform for in vitro and in vivo screening and S StemCells, Inc. toxicity assays using the same human target cells of interest across the entire continuum from discovery to preclinical testing Grace Wong, CEO, Actokine Therapeutics •  ultiplexed HCA and live cell assays to improve validation of leads M •  ase studies of optimized protocols for automated human neural stem C cell production and of a proliferation screen 16:40 Chair’s closing remarks Thorsten Gorba Director, CNS Assay Screening and Development StemCells, Inc. 16:50 End of Conference Cell-Based Assays: World Market Prospects 2011-2026 RE Are you looking for pharmaceutical R&D market data - answers to save you time and effort, aiding decisions? PO Our new report shows you spending trends and revenue prospects for cell-based assays in pharma. RT We give market data for 2009 to 2026.
  • 5. Partners Cell Based Assays Americas July 19th - 20th, 2012, Boston, USASilver Sponsor InvivoSciences LLC is a frontier in developing next generation 3D cell culture and assay systems Sponsorship and to provide unprecedented solutions in biomedical research, cosmetics, and toxicology screening. exhibition opportunities: Current in vitro studies are confined largely to 2D cell culture models. However, most human cells have 3D interactions. Application of our products, a high-throughput screening device (Palpator™) This event offers a unique opportunity to and 3D cell culture systems, can narrow the gap between 2D cell culture studies and in vivo meet and do business with some of the analysis. Effects of drug candidates, chemicals, and gene products on the physiological properties of key players in the pharmaceutical and3D cell culture systems, forming reconstituted tissues, that mimic in vivo tissue/organ functions are quantified rapidly biotech industries. If you have a serviceand cost-effectively. For further information please visit www.invivosciences.com or product to promote, you can do so at this event by:Exhibitors • Hosting a networking drinks Matrical Bioscience is a leading supplier in the life-science research market through reception matrical the development of innovative, quality products targeted for drug discovery and bioscience genomics applications. All products are cooperatively designed between our engineers • Taking an exhibition space at theand biochemists/biologists to ensure a reliable cost-effective solution that meets or exceeds our customers’ conferenceexpectations. Matrical Bioscience is a worldwide supplier of automated storage platforms (MiniStore), automated • Advertising in the delegatebiobanking systems (NitroStore), automated assay platform (AutoMAP), automated cell culture systems documentation pack(MACCS), high throughput sonication devices (SonicMan), universal microplate washer (SQUIRT), consumablemicrowell plates in 96, 384, & 1536 formats and tube technology for chemical and biological sample storage. • Providing branded bags, pens, gifts,For further information please visit www.matrical.com etc. If you would like more information on TAP Biosystems provides advanced automation systems and services in 4 key the range of sponsorship or exhibition application areas: cell-based testing, regenerative medicine, drug discovery and possibilities for visiongains Cell Based bioprocessing TAP will be exhibiting and presenting the new RAFT™ 3D cell Assays Americas Conference,culture system. RAFT can be used as a platform technology to support assay development and secondary screening please contact us.programs, as well as a broad range of cell biology research applications. Damian Gorman, SCIVAX Corporation is a Nano-technology company featuring Nano-imprinting. SCIVAX +44 (0)20 7549 9934 focus on commercialization of the Nano-imprinting application, and one of the products damian.gorman@ is our NanoCulture® Plate for biotechnology application. NanoCulture® Plate is a visiongainglobal.comREADY-TO-USE SBS format microplate, which can form 3D spheroids on the well bottom film with nano-imprinted micro scaffold, without any matix and troublesome procedures. 3D spheroids can be cultured justby adding standard cell culture medium to the well, and seeding. 3D spheroids of various cell types culturedon our NanoCulture® Plate show in vivo like characters compared to monolayer cells, and is being used for About visiongain:various application such as cancer drug screening, cell based assay, IPS/ES cell culture, etc. V  isiongain is a specialist businessFor further information please visit www.scivax.com/usa/ information company focused on providing cutting edge products andMedia Partners services across the Pharmaceutical/ PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Biotech, Telecommunications, Defence Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides and Finance sectors, which includedynamic real-time news, features, events listings and international jobs to industry professionals across Europe reports, conferences, online daily newsand the US. and offline news analysis and bespokeFor further information please email: corporate@pharmiweb.com consultancy. With a commitment to innovation and excellence, visiongain BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located offers flexible solutions to meet our in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s clients’ business intelligence needs,biotech and pharma information and market to make it universally accessible and useful for scientific and providing the right informationbusiness processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE at the right time to facilitate theplatform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers commercial decision-making process.companies completed internet public relations, publication and marketing solutions. One of the mains goals Our pharmaceutical products includeof BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, Pharma Business Daily, the leadingpharmaceutical and life science activities. daily email newsletter for theFor further information please visit www.biotechnology-europe.com pharmaceutical, biotech and healthcare industries, and a range of independent, InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, high-quality, in-depth reports covering services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. focused and topical areas of concern.For further information please visit: www.In-Pharm.com Our pharmaceutical conferences address the hottest commercial, Future Pharmaceuticals has forged powerful relationships with key industry leaders to Driving the Industry Forward | www.futurepharmaus.com regulatory and technical topics and provide a platform for successful brand recognition, and for senior decision-makers to provide an ideal forum for debatehave the means to procure and plan implementation strategies based on the topics covered. Positioned to and networking for pharmaceuticalbe an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future professionals from around the world.Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsiveaudience, bridging the gap between the industries’ top issues and the solutions top-tier vendors can provide. F  or further information, pleaseFor further information please visit: www.futurepharmaus.com visit www.visiongain.com
  • 6. Registration Form Cell Based Assays Americas July 19th - 20th, 2012, Boston, USAFor multiple bookings Cell Based AssaysPhotocopy this form Conf. code VG AmericasStandard Prices July 19th – 20th, 2012 Location: The Seaport HotelConference only Fee: £1299 (USD* 2006) Address:  One Seaport Lane Boston MA 02210 USA*USD price is estimate onlyPromotional Literature DistributionDistribution of your company’s promotional literature to all conference attendees How to book Fee: £999 VAT: £199.80 Total: £1198.80 Email: conferences@visiongainglobal.com Web: http://www.visiongain.com/CellBasedAssaysUSADetails UK Office: Tel: +44 (0) 20 7336 6100 Fax: +44 (0) 20 7549 9932 Forename: Surname: Visiongain Ltd 230 City RoadJob Title: Company: London EC1V 2QY UKMain Switchboard Number: General informationAddress: Venue: The Seaport Hotel, One Seaport Lane, Boston, MA 02210, USA Front Desk Phone: 001 617.385.4000 | Front Desk Fax: 001 617.385.4001 http://www.seaportboston.com/ Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guaranteeCountry: Postcode: may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the right to charge interest on unpaid invoices. Substitutions/name changes or cancellations: There is a 50% liability on all bookings oncePhone: Fax: made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoiceEmail: must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes andSignature: substitutions must be from the same company or organisation and are not transferable between countries. Please note that discounted delegates places at a visiongain event are non refundable.I confirm that I have read and agree to the terms and conditions of booking Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, excluding substitutions/name changes, requested by the customer. This will be charged to the customer by credit card prior to the changes being made.Methods of payment Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelledPayment must be made in sterling due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or By Mail: Complete and return your signed registration form together with your cheque expenses, which may be incurred by the customer as a consequence of the event being postponed or payable to Visiongain Ltd and send to: visiongain Ltd, 230 City Road, London, EC1V 2QY, UK cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the cost of the registration, travel and expenses. By Fax: Complete and fax your signed registration form with your credit card details Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1988. Your personal information contained in this form may be used to update you on to +44 (0) 20 7549 9932 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,  Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 By EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. Please allow approximately 30 days for your removal or update request to be applied to our database. By Bank Transfer Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect. Please debit my credit card: Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. Access MasterCard Visa American Express This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain).Card number: VAT: VAT will be charged at the local rate on each conference. TaxPort USA Corp. specializes in recovering cross-border VAT. Delegates may be able to recover VAT incurred by contacting TaxPortExpiry Date: USA Corp.on: Tel: USA 802.860.0250 or +1.888.298.8296, Europe +41(0)21 310 01 50 or via email on: vat@taxport-usa.com, vat@taxport-switzerland.com, vat@taxport-uk.com. For further information please check Terms and Conditions on the visiongin.com web siteSecurity number (last 3 digits on back of credit card): How we will contact you: Visiongain Ltd’s preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.Signature: Unable to attendCardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send with your payment. You will receive speaker talks in PDFs two weeks after the event. Yes, please send me speaker talks Price£550 VAT:£110 Total:£660News updates Office use onlyPlease tick if you do not want to receive email news updates in the future www.visiongain.com/CellBasedAssaysUSA